EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Engineering Affibody Binders to Death Receptor 5 and Tumor Necrosis Factor Receptor 1 With Improved Stability

Gregory H Nielsen, Jonathan N Sachs, Benjamin J Hackel iD

Biotechnology and Bioengineering · 2025

DOI: 10.1002/bit.28954 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2025. Written by Gregory H Nielsen and 2 co-authors. Institution: Department of Chemical Engineering and Materials Science, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA. Major MEDLINE topics: Protein Engineering, Recombinant Fusion Proteins, Receptors, Tumor Necrosis Factor, Type I, Receptors, TNF-Related Apoptosis-Inducing Ligand. 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIBIB NIH HHS, NIGMS NIH HHS, This research was supported by the National Institutes of Health (R01 EB028274 and R01 GM146372)..

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Protein developability is an important, yet often overlooked, aspect of protein discovery campaigns that is a key driver of utility. Recent advances have improved developability screening capacity, making it an increasingly viable option in early‐stage discovery. Here, we engineered one component of developability, stability, of two affibody proteins—one that targets death receptor 5 and another that targets tumor necrosis factor receptor 1—previously evolved to bind receptor and non‐competitively inhibit signaling via conformational modulation. Starting from an error‐prone PCR library of each affibody, variants were screened via yeast surface display binder selections, including depletion of non‐specific binders, followed by developability assessment using the on‐yeast protease and yeast display level assays. Multiplex deep sequencing identified variants for further evaluation. Purified variants exhibited elevated stability—8°C to 14°C increase in T m,app —with maintained 1–2 nM affinity for the TNFR1 affibody and 30‐fold improvement in the DR5 affibody affinity to 0.8 nM.

Subjects

MeSH terms (MEDLINE)

Protein EngineeringRecombinant Fusion ProteinsReceptors, Tumor Necrosis Factor, Type IReceptors, TNF-Related Apoptosis-Inducing LigandProtein StabilityHumansProtein Binding

Author keywords

affibodydeath receptor 5developabilityevolutiontumor necrosis factor receptor

Substances

Recombinant Fusion ProteinsReceptors, Tumor Necrosis Factor, Type IReceptors, TNF-Related Apoptosis-Inducing LigandTNFRSF1A protein, human

Authors and institutions

  • Department of Chemical Engineering and Materials Science, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.
  • Department of Biomedical Engineering, University of Minnesota Twin Cities, Minneapolis, Minnesota, USA.

ORCID profiles: Benjamin J Hackel

Funding

  • NIBIB NIH HHS
  • NIGMS NIH HHS
  • This research was supported by the National Institutes of Health (R01 EB028274 and R01 GM146372).
  • National Institutes of Health

Cite

APA

Nielsen, G. H., Sachs, J. N., & Hackel, B. J. (2025). Engineering Affibody Binders to Death Receptor 5 and Tumor Necrosis Factor Receptor 1 With Improved Stability. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28954

Vancouver

Nielsen GH, Sachs JN, Hackel BJ. Engineering Affibody Binders to Death Receptor 5 and Tumor Necrosis Factor Receptor 1 With Improved Stability. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28954

BibTeX
@article{Nielsen2025,
  author = {Nielsen, Gregory H and Sachs, Jonathan N and Hackel, Benjamin J},
  title = {Engineering Affibody Binders to Death Receptor 5 and Tumor Necrosis Factor Receptor 1 With Improved Stability},
  journal = {Biotechnology and Bioengineering},
  year = {2025},
  doi = {10.1002/bit.28954}
}
Start for free →